Hepatocellular carcinoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Atezolizumab and Bevacizumab Variant #01 | — | R 61 241 | 21d | — | ~19.2 mo | ~2 | ~R 122 482 PFS proxy · indirect | 1 |
Observation Partial | — | — | — | — | — | — | — | 1 |
TACE monotherapy Variant #01 | — | — | — | — | — | — | — | 1 |
Placebo Partial | — | — | — | ~2.3 mo | ~7.6 mo | — | — | 16 |
4 of 4 regimens shown